Citation Impact
Citing Papers
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Nonheparin Anticoagulants for Heparin-Induced Thrombocytopenia
2013
CLINICAL PRACTICE. Heparin-Induced Thrombocytopenia.
2015
Heparin-Protein Interactions
2002 Standout
Incidence and clinical significance of anti‐PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin‐induced thrombocytopenia
2006
Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need?
2005
Manipulation of cell surface macromolecules by flaviviruses
2003
A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis
1998 Standout
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
2001 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
An Improved Definition of Immune Heparin-Induced Thrombocytopenia in Postoperative Orthopedic Patients
2003
Paraneoplastic Syndromes Involving the Nervous System
2003 Standout
Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis
2001
Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention
2004
Antithrombotic Therapy for VTE Disease
2016 Standout
Drug-Induced Thrombocytopenia
2007
Risk Factors for Heparin-Induced Thrombocytopenia Type II in Aneurysmal Subarachnoid Hemorrhage
2011
Heparin-induced thrombocytopenia with thrombosis: Incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution
1997
Heparin-Induced Thrombocytopenia
1998
A Spontaneous Prothrombotic Disorder Resembling Heparin-induced Thrombocytopenia
2008
Temporal Aspects of Heparin-Induced Thrombocytopenia
2001 Standout
Mammalian GPI proteins: sorting, membrane residence and functions
1997
Whole blood coagulation on protein adsorption-resistant PEG and peptide functionalised PEG-coated titanium surfaces
2004 StandoutNobel
Antithrombotic Therapy for VTE Disease
2012 Standout
A Novel PF4-Dependent Platelet Activation Assay Identifies Patients Likely to Have Heparin-Induced Thrombocytopenia/Thrombosis
2016
Incidence and clinical relevance of heparin‐induced antibodies in patients with deep vein thrombosis treated with unfractionated or low‐molecular‐weight heparin
2002
Intrinsic Immunity Shapes Viral Resistance of Stem Cells
2017 StandoutNobel
Immune Thrombocytopenic Purpura
2002 Standout
Heparin-Induced Thrombocytopenia
2006 Standout
Pentosan polysulfate‐induced thrombocytopenia and thrombosis
1994
Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis
1995 Standout
HEPARIN-INDUCED THROMBOCYTOPENIA, PARADOXICAL THROMBOEMBOLISM, AND OTHER SIDE EFFECTS OF HEPARIN THERAPY
1998
Prevention of Venous Thromboembolism
2004 Standout
The Hazards of Scoring the Quality of Clinical Trials for Meta-analysis
1999 Standout
Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin
1995 Standout
The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer
2010
Heparin‐induced thrombocytopenia and thrombosis: clinical and laboratory studies
1993
Treatment and Prevention of Heparin-Induced Thrombocytopenia
2012
A 14-year study of heparin-induced thrombocytopenia
1996 Standout
Severe Adverse Cutaneous Reactions to Drugs
1994 Standout
Heparin‐induced thrombocytopenia: mechanism of interaction of the heparin‐dependent antibody with platelets
1989
Prevention of Venous Thromboembolism
2008 Standout
Advances in the diagnosis of idiopathic thrombocytopenic purpura
2000
The Pathophysiology of Heparin-Induced Thrombocytopenia
2005
Heparin-induced thrombocytopenia in hemodialysis patients
1996
A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease
1997 Standout
Complications of Femoral and Subclavian Venous Catheterization in Critically Ill Patients<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
2001 Standout
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia
2016
Heparin-induced multiple electrode aggregometry is a promising and useful functional tool for heparin-induced thrombocytopenia diagnosis: Confirmation in a prospective study
2012
High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review
2019
Hierarchical Assembly of Model Cell Surfaces: Synthesis of Mucin Mimetic Polymers and Their Display on Supported Bilayers
2007 StandoutNobel
Impact of the patient population on the risk for heparin-induced thrombocytopenia
2000 Standout
Venous thromboembolism in trauma patients: A review
2001
Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range
2000
Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies
2000
Regulatory T Cells Control PF4/Heparin Antibody Production in Mice
2019
Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia
1994
Molecular Cloning and Characterization of the Human Folate-binding Protein cDNA from Placenta and Malignant Tissue Culture (KB) Cells
1989
Recombinant Hirudin (Lepirudin) Provides Safe and Effective Anticoagulation in Patients With Heparin-Induced Thrombocytopenia
1999
Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.
1994
Differential Effects of Anticoagulants on the Activation of Platelets Ex Vivo
1997
Synthetic Analogues of Glycosylphosphatidylinositol-Anchored Proteins and Their Behavior in Supported Lipid Bilayers
2007 StandoutNobel
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
Guidelines for the Primary Prevention of Stroke
2014 Standout
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
2008 Standout
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
Cerebral venous sinus thrombosis associated with spontaneous heparin-induced thrombocytopenia syndrome after total knee arthroplasty
2020
Homogeneous Glycopeptides and Glycoproteins for Biological Investigation
2002 StandoutNobel
Insertion of an intracisternal A particle within the 5'-regulatory region of a gene encoding folate-binding protein in L1210 leukemia cells in response to low folate selection. Association with increased protein expression.
1992 StandoutNobel
Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4
2013
Defining an Antigenic Epitope on Platelet Factor 4 Associated With Heparin-Induced Thrombocytopenia
1998
A chemical approach to unraveling the biological function of the glycosylphosphatidylinositol anchor
2007 StandoutNobel
COAGULATION DISORDERS IN CANCER
1996
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
First Workshop for Detection of Heparin-induced Antibodies: Validation of the Heparin-induced Platelet-activation Test (HIPA) in Comparison with a PF4/Heparin ELISA
1999
Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia
1996
Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage
2012 Standout
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
2021 Standout
Low-Molecular-Weight Heparins
1997 Standout
The Glycosylphosphatidylinositol Anchor: A Complex Membrane-Anchoring Structure for Proteins
2008 StandoutNobel
Management of Deep Vein Thrombosis and Pulmonary Embolism
1996
Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic itinerary, resulting in retention of low-density lipoprotein on the cell surface
2002 StandoutNobel
Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range
2000
Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies
2011
Endothelial cells in physiology and in the pathophysiology of vascular disorders.
1998 Standout
The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study
2003
Chemical and Biological Strategies for Engineering Cell Surface Glycosylation
2001 StandoutNobel
Antibodies to Macromolecular Platelet Factor 4-Heparin Complexes in Heparin-induced Thrombocytopenia: a Study of 44 Cases
1995
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
2021 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
The incidence of heparin-induced thrombocytopenia Type II in patients with subarachnoid hemorrhage treated with heparin versus enoxaparin
2008
Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia
2001 Standout
Synthesis of Lipidated Green Fluorescent Protein and Its Incorporation in Supported Lipid Bilayers
2005 StandoutNobel
Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis
2005 Standout
The molecular immunology of human platelet proteins
1992
Antibodies to Platelet Factor 4–Heparin After Cardiopulmonary Bypass in Patients Anticoagulated With Unfractionated Heparin or a Low-Molecular-Weight Heparin
1999
Characterization of two cDNAs encoding folate-binding proteins from L1210 murine leukemia cells. Increased expression associated with a genomic rearrangement.
1991 StandoutNobel
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
2021 Standout
Works of JW Smith being referenced
Gova/b alloantigen system on human platelets
1990
Heparin-induced thrombocytopenia: laboratory studies
1988
Heparin-induced thrombocytopenia: laboratory studies
1988
Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4
1994
Characterization and localization of the Gova/b alloantigens to the glycosylphosphatidylinositol-anchored protein CDw109 on human platelets
1995